The device is suitable for treating a broad range of wounds such as pressure ulcers, diabetic ulcers, and surgical wounds. Credit: sfam_photo / Shutterstock.

Regenerative medicine company StimLabs has announced the availability of Corplex P, a medical device for wound care, in the US.

Corplex P is claimed to be the first and only device derived from the human umbilical cord extracellular matrix (ECM).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It is specifically designed to aid in the healing of challenging wounds. Its unique composition, which includes key connective tissue matrix components such as collagens and glycosaminoglycans, provides a moist environment conducive to wound healing.

The device’s processing technique preserves these vital components.

The ability of Corplex P to regulate moisture exchange is one of its primary benefits. Its hydrophilic nature, particularly due to the presence of hyaluronic acid, contributes to its absorptive properties.

See Also:

Its particulate format not only allows for efficient moisture management but also ensures that the device conforms to the wound bed, promoting better integration into the healing tissue.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Corplex P can be used for a wide variety of wounds, including pressure ulcers, diabetic ulcers, and surgical wounds. Its optimised design for complex wound beds, natural resorption into the wound, and facilitation of a moist wound environment underscore its key advantages.

StimLabs founder and CEO John Daniel said: “Chronic and acute wounds present a significant healthcare challenge, affecting millions of individuals each year.

“With Corplex P, StimLabs aims to address this challenge by providing clinicians and patients with an advanced solution for wound management.

“Corplex P offers an opportunity for a better quality of life for those in need of care and since its limited release, healthcare practitioners have shown excitement for the impact it’s making. We’re excited to now make this available nationally.”

In February this year, the company received 510(k) clearance from the US Food and Drug Administration for the Corplex P device.